DE69330277D1 - Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut - Google Patents

Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut

Info

Publication number
DE69330277D1
DE69330277D1 DE69330277T DE69330277T DE69330277D1 DE 69330277 D1 DE69330277 D1 DE 69330277D1 DE 69330277 T DE69330277 T DE 69330277T DE 69330277 T DE69330277 T DE 69330277T DE 69330277 D1 DE69330277 D1 DE 69330277D1
Authority
DE
Germany
Prior art keywords
target cells
cells
transcutaneous
photo
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330277T
Other languages
English (en)
Other versions
DE69330277T2 (de
Inventor
Anna M Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QLT INC., VANCOUVER, BRITISH COLUMBIA, CA
Original Assignee
Quadra Logic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Technologies Inc filed Critical Quadra Logic Technologies Inc
Application granted granted Critical
Publication of DE69330277D1 publication Critical patent/DE69330277D1/de
Publication of DE69330277T2 publication Critical patent/DE69330277T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69330277T 1992-09-21 1993-09-20 Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut Expired - Fee Related DE69330277T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94811392A 1992-09-21 1992-09-21
PCT/CA1993/000382 WO1994006424A1 (en) 1992-09-21 1993-09-20 Transcutaneous in vivo activation of photosensitive agents in blood

Publications (2)

Publication Number Publication Date
DE69330277D1 true DE69330277D1 (de) 2001-07-05
DE69330277T2 DE69330277T2 (de) 2002-04-18

Family

ID=25487290

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330277T Expired - Fee Related DE69330277T2 (de) 1992-09-21 1993-09-20 Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut

Country Status (21)

Country Link
US (2) US5484803A (de)
EP (1) EP0660712B1 (de)
JP (2) JP3598306B2 (de)
AT (1) ATE201596T1 (de)
AU (1) AU681088B2 (de)
CA (1) CA2144327C (de)
DE (1) DE69330277T2 (de)
DK (1) DK0660712T3 (de)
ES (1) ES2160600T3 (de)
FI (1) FI951295A (de)
GR (1) GR3036479T3 (de)
HU (1) HU220251B (de)
IL (1) IL107035A (de)
NO (1) NO951066L (de)
NZ (1) NZ255302A (de)
PL (1) PL308116A1 (de)
PT (1) PT660712E (de)
SK (1) SK35295A3 (de)
TW (1) TW241204B (de)
WO (1) WO1994006424A1 (de)
ZA (1) ZA936968B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6710066B2 (en) * 1989-07-28 2004-03-23 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US20020058008A1 (en) * 1989-07-28 2002-05-16 Kennedy James C. Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5798238A (en) * 1990-04-16 1998-08-25 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US5587490A (en) * 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US20040110819A1 (en) * 1991-10-28 2004-06-10 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
EP0947222B1 (de) * 1992-11-20 2006-04-12 The University Of British Columbia Verfahren zur Aktivierung von photoempfindlichen Mitteln
WO1996039188A1 (en) * 1995-06-05 1996-12-12 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
AU723016B2 (en) * 1995-11-06 2000-08-17 New York Blood Center, Inc., The Viral inactivation treatment of red blood cells using phthalocyanines and red light
US5895786A (en) 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
US6159733A (en) * 1996-06-20 2000-12-12 New York Blood Center, Inc. Method for photoinactivating malignant cells
US5922278A (en) 1996-11-19 1999-07-13 Baxter International Inc. Method and apparatus for inactivating contaminants in biological fluid
US5742380A (en) * 1996-12-31 1998-04-21 Ronn Avigdor M Plasma assay spectrometer
US6103706A (en) * 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US6010890A (en) * 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US5856566A (en) 1997-09-02 1999-01-05 Dusa Pharmaceuticals, Inc. Sterilized 5-aminolevulinic acid
US6159178A (en) 1998-01-23 2000-12-12 Heartport, Inc. Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
JP2002534483A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 代謝性骨障害または骨転移のための治療的組成物
US6454789B1 (en) * 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
AU2412800A (en) * 1999-01-15 2000-08-01 Light Sciences Corporation Noninvasive vascular therapy
US6376483B1 (en) 1999-05-27 2002-04-23 Miravant Pharmaceuticals, Inc. Bacteriochlorins and bacteriopurpurins useful as photoselective compounds for photodynamic therapy and a process for their production
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
DE19960705A1 (de) * 1999-12-16 2001-06-21 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur Herstellung eines autologen Immunisierungsimpfstoffes gegen Krebserkrankungen (Tumorvakzine)
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
EP1267935A2 (de) * 2000-01-12 2003-01-02 Light Sciences Corporation Behandlung von augenerkrankungen
KR100365151B1 (ko) * 2000-05-08 2003-02-11 김형락 어류 병원성 세균과 바이러스의 감염 예방 및 치료를 위한δ-아미노레불린산의 신규한 용도
DE10034673C1 (de) 2000-07-17 2002-04-25 Medac Klinische Spezialpraep Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung
EP2248536A3 (de) 2000-12-14 2010-12-08 The General Hospital Corporation doing business as Massachusetts General Hospital Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
DE60141758D1 (en) 2000-08-16 2010-05-20 Gen Hospital Corp Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
WO2002100326A2 (en) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
EP1401479B1 (de) * 2001-06-04 2007-04-18 The General Hospital Corporation Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
DE10162712A1 (de) * 2001-12-19 2003-07-17 Blutspendienst Der Landesverba Verfahren zur Inaktivierung von Bakterien und Leukozyten in Blut oder Blutprodukten
EP1467760A2 (de) * 2002-01-23 2004-10-20 Light Sciences Corporation Systeme und verfahren zur photodynamischen therapie
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
EP2036908A3 (de) 2002-07-02 2009-05-13 Health Research, INC. Effiziente Synthese von Pyropheophorbid-A-Derivaten
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
WO2004099375A2 (en) * 2003-04-30 2004-11-18 The General Hospital Corporation Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use therof
CA2527522A1 (en) * 2003-05-29 2004-12-09 Kenneth Chang Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
FR2857264A1 (fr) * 2003-07-09 2005-01-14 Maco Pharma Sa Procede d'inactivation photodynamique des pathogenes au moyen d'ala
GB0424833D0 (en) 2004-11-10 2004-12-15 Photocure Asa Method
US8585707B2 (en) 2006-06-07 2013-11-19 Gary S. Rogers Continuous low irradiance photodynamic therapy method
US20080164224A1 (en) * 2007-01-04 2008-07-10 Whirlpool Corporation System for connecting mechnically dissimilar consumer electronic devices to an adaptor or a host
EP2644228A1 (de) 2007-06-27 2013-10-02 The General Hospital Corporation Verfahren und Vorrichtung zur optischen Unterdrückung der photodynamischen Therapie
US20090062724A1 (en) * 2007-08-31 2009-03-05 Rixen Chen System and apparatus for sonodynamic therapy
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
AU2012240016B2 (en) 2011-04-07 2016-11-10 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4961920A (en) * 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses

Also Published As

Publication number Publication date
NO951066L (no) 1995-05-19
PT660712E (pt) 2001-11-30
HU220251B (hu) 2001-11-28
EP0660712A1 (de) 1995-07-05
JPH08501301A (ja) 1996-02-13
FI951295A0 (fi) 1995-03-20
US5736563A (en) 1998-04-07
AU681088B2 (en) 1997-08-21
ZA936968B (en) 1994-04-12
HUT70966A (en) 1995-11-28
EP0660712B1 (de) 2001-05-30
NZ255302A (en) 2001-04-27
JP3598306B2 (ja) 2004-12-08
ES2160600T3 (es) 2001-11-16
SK35295A3 (en) 1996-05-08
ATE201596T1 (de) 2001-06-15
CA2144327C (en) 2002-08-06
DE69330277T2 (de) 2002-04-18
IL107035A (en) 1998-12-27
DK0660712T3 (da) 2001-08-27
CA2144327A1 (en) 1994-03-31
NO951066D0 (no) 1995-03-20
TW241204B (de) 1995-02-21
WO1994006424A1 (en) 1994-03-31
US5484803A (en) 1996-01-16
JP2001316288A (ja) 2001-11-13
AU4940593A (en) 1994-04-12
FI951295A (fi) 1995-05-17
GR3036479T3 (en) 2001-11-30
PL308116A1 (en) 1995-07-24
IL107035A0 (en) 1993-12-28

Similar Documents

Publication Publication Date Title
DE69330277D1 (de) Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
DE69831567D1 (de) Einrichtung zur behandlung von herzarrhythien
CA2400801A1 (en) Treatment of congestive heart failure by pretreated autologous blood
FR2763247B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur a reduction des episodes d'arythmie, notamment d'arythmie auriculaire
FR2772622B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite configurable
DE69623390D1 (de) Aktive implantierbare medizinische Vorrichtung, insbesondere Herzschrittmacher oder Defibrillator
WO1999012951A8 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
DE69824119D1 (de) Implantierbare aktive medizinische Einrichtung, insbesondere Herzstimulator, gesteuert von wenigstens einem physiologischen Parameter
ATE22655T1 (de) Infusionsloesungen zur herztherapie.
EA199900724A1 (ru) Способы лечения, профилактики и защиты кровеносных сосудов от повреждений (варианты), способы лечения и профилактики различных видов гипертензии, атеросклероза (варианты)
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
DE69624958D1 (de) Katheter, insbesondere zur Behandlung von Herzarrhythmie
MX9407876A (es) Formulaciones de hongos entomopatogenos para uso como insecticidas biologicos.
DE10031851A1 (de) Photodynamische Behandlung und UV-B-Bestrahlung einer Thrombozyten-Suspension
DE69421253D1 (de) Feste insectizide Formulierung
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
ES2071639T3 (es) Una dispersion sobre la base de carbamato y un agente inhibidor del crecimiento de particulas y un metodo para tratar cultivos de remolacha.
DE69937797D1 (de) Alpha-emittierende konstrukte sowie deren verwendung
RU96118110A (ru) Предупреждение разрушения эритроцитов, стерилизованных фталоцианином и светом в присутствии витамина e и его производных
RU95103472A (ru) Способ лечения заразных форм сифилиса
RU94042540A (ru) Способ лечения воспаленных тканей организма
RU97113539A (ru) Способ лечения заболеваний, вызываемых микроорганизмами
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу
RU95104173A (ru) Способ нормализации функций органов и систем биообъекта

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: QLT INC., VANCOUVER, BRITISH COLUMBIA, CA

8339 Ceased/non-payment of the annual fee